Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers

被引:31
|
作者
Findlow, Jamie [1 ,2 ]
Bai, Xilian [1 ,2 ]
Findlow, Helen [1 ,2 ]
Newton, Emma [1 ,2 ]
Kaczmarski, Ed [1 ,2 ]
Miller, Elizabeth [3 ]
Borrow, Ray [1 ,2 ,4 ]
机构
[1] Publ Hlth England, Publ Hlth Lab, Manchester M13 9WZ, Lancs, England
[2] Manchester Royal Infirm, Manchester Med Microbiol Partnership, Manchester M13 9WZ, Lancs, England
[3] Publ Hlth England, Immunisat Dept, Hlth Protect Serv, London NW9 5EQ, England
[4] Univ Manchester, Inflammat Sci Res Grp, Sch Translat Med, Manchester M13 9PL, Lancs, England
关键词
Meningococcal; Vaccine; 4CMenB; ACWY-CRM; Laboratory workers; NEISSERIA-MENINGITIDIS SEROGROUP; IMMUNOLOGICAL HYPORESPONSIVENESS; POLYSACCHARIDE VACCINATION; GLYCOCONJUGATE VACCINE; UNITED-KINGDOM; HUMAN IMMUNITY; GROUP C; ANTIBODIES; ADULTS; STANDARDIZATION;
D O I
10.1016/j.vaccine.2015.05.027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Safety precautions for laboratory staff working with meningococci should primarily rely on laboratory procedures preventing exposure to aerosols containing viable meningococci. Despite this, vaccination is a key component of protection in the occupational setting. In the UK in 2009, there were no licensed vaccines for meningococcal capsular group B or conjugate vaccines for capsular groups A, C, W and Y. We therefore undertook a Phase II trial in laboratory workers to investigate the safety and immunogenicity of a four component group B vaccine (4CMenB) and a quadrivalent group A, C,W and Y conjugate vaccine (ACWY-CRM). Enrolment was open to staff aged 18-65 years at the Public Health Laboratory, Manchester who may have had a potential occupational exposure risk to meningococci. 4CMenB was administered at 0,2 and 6 months in the non-dominant arm and ACWY-CRM concomitantly at 0 months in the dominant arm. Pre- and post-vaccination blood samples were taken and analysed by the serum bactericidal antibody (SBA) assay against A, C, W and Y strains and a panel of seven diverse group B strains. Diary cards were used to record any local and systemic reactions following each vaccination. In total, 38 staff were enrolled and received initial vaccinations with 31 completing the trial per protocol. Both vaccines were proven safe, with local reactogenicity being more commonly reported following 4CMenB than ACWY-CRM. High proportions of subjects had putative protective SBA titres pre-vaccination, with 61-84 and 61-87% protected against A, C, W and Y strains and diverse MenB strains, respectively. Post-vaccination, SBA titres increased with 95-100 and 90-100% of subjects with protective SBA titres against A, C, W and Y strains and diverse MenB strains, respectively. These data suggest that 4CMenB and ACWY-CRM are safe when administered concomitantly and have the potential to enhance protection for laboratory workers. Crown Copyright (C) 2015 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:3322 / 3330
页数:9
相关论文
共 50 条
  • [41] Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial
    Macias Parra, Mercedes
    Gentile, Angela
    Vazquez Narvaez, Jorge Alejandro
    Capdevila, Alejandro
    Minguez, Angel
    Carrascal, Monica
    Willemsen, Arnold
    Bhusal, Chiranjiwi
    Toneatto, Daniela
    VACCINE, 2018, 36 (50) : 7609 - 7617
  • [42] Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study
    Dhingra, M. S.
    Namazova-Baranova, L.
    Arredondo-Garcia, J. L.
    Kim, K. -H.
    Limkittikul, K.
    Jantarabenjakul, W.
    Perminova, O.
    Kobashi, I. A. R.
    Bae, C. -W.
    Ojeda, J.
    Park, J.
    Chansinghakul, D.
    B'Chir, S.
    Neveu, D.
    Bonaparte, M.
    Jordanov, E.
    EPIDEMIOLOGY AND INFECTION, 2021, 149
  • [43] Immunogenicity and Safety of a 3-and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants
    Block, Stan L.
    Shepard, Julie
    Garfield, Hartley
    Xie, Fang
    Han, Linda
    Dull, Peter M.
    Smolenov, Igor
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (02) : E48 - E59
  • [44] First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England
    Ladhani, Shamez N.
    Campbell, Helen
    Andrews, Nick
    Parikh, Sydel R.
    White, Joanne
    Edelstein, Michael
    Clark, Stephen A.
    Lucidarme, Jay
    Borrow, Ray
    Ramsay, Mary E.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (07) : E1661 - E1668
  • [45] Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults
    Lee, Hoan Jong
    Chung, Moon-Hyun
    Kim, Woo Joo
    Hong, Young Jin
    Choi, Kyong Min
    Lee, Jina
    Oh, Chi Eun
    Welsch, Jo Anne
    Kim, Kyung-Hyo
    Hong, Ki Bae
    Dagnew, Alemnew F.
    Bock, Hans
    Dull, Peter M.
    Odrljin, Tatjana
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 28 : 204 - 210
  • [46] Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom
    Southern, Jo
    Borrow, Ray
    Andrews, Nick
    Morris, Rhonwen
    Waight, Pauline
    Hudson, Michael
    Balmer, Paul
    Findlow, Helen
    Findlow, Jamie
    Miller, Elizabeth
    CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (02) : 194 - 199
  • [47] A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide-CRM197 with a meningococcal group C conjugate vaccine in healthy infants:: Challenge phase
    Riddell, Anna
    Buttery, Jim P.
    McVernon, Jodie
    Chantler, Tracey
    Lane, Laura
    Bowen-Morris, Jane
    Diggle, Linda
    Morris, Rhonwen
    Lockhart, Steven
    Pollard, Andrew J.
    Cartwright, Keith
    Moxon, E. Richard
    VACCINE, 2007, 25 (19) : 3906 - 3912
  • [48] Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial
    Davis, Kimberly
    Pinto, Marta Valente
    Andrews, Nick J.
    Goldblatt, David
    Borrow, Ray
    Findlow, Helen
    Southern, Jo
    Partington, Jo
    Plested, Emma
    Patel, Sima
    Holland, Ann
    Matheson, Mary
    England, Anna
    Hallis, Bassam
    Miller, Elizabeth
    Snape, Matthew D.
    LANCET INFECTIOUS DISEASES, 2021, 21 (05): : 688 - 696
  • [49] Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents
    Vesikari, Timo
    Wysocki, Jacek
    Beeslaar, Johannes
    Eiden, Joseph
    Jiang, Qin
    Jansen, Kathrin U.
    Jones, Thomas R.
    Harris, Shannon L.
    O'Neill, Robert E.
    York, Laura J.
    Perez, John L.
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2016, 5 (02) : 180 - 187
  • [50] Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix in Healthy Adolescents: A Randomized Phase IIIb Multicenter Study
    Diez-Domingo, Javier
    Simko, Robert
    Icardi, Giancarlo
    Chong, Chan Poh
    Zocchetti, Celine
    Syrkina, Olga
    Bchir, Siham
    Bertrand-Gerentes, Isabelle
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (08) : 1835 - 1859